Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published May 23, 2017 | Published
Journal Article Open

Modulation of estrogen related receptor alpha activity by the kinesin KIF17

Abstract

Estrogen-related receptor alpha (ERR1) is an orphan nuclear receptor that can bind transcriptional co-activators constitutively. ERR1 expression correlates with poor patient outcomes in breast cancer, heightening interest in this nuclear receptor as a therapeutic target. Because ERR1 has no known regulatory ligand, a major challenge in targeting its activity is to find cellular or synthetic modulators of its function. We identified an interaction between ERR1 and KIF17, a kinesin-2 family microtubule motor, in a yeast-2-hybrid screen. We confirmed the interaction using in vitro biochemical assays and determined that binding is mediated by the ERR1 ligand-binding/AF2 domain and the KIF17 C-terminal tail. Expression of KIF17 tail domain in either ER-negative or ER-positive breast cancer epithelial cells attenuated nuclear accumulation of newly synthesized ERR1 and inhibited ERR1 transcriptional activity. Conversely, ERR1 transcriptional activity was elevated significantly in KIF17 knock-out cells. Sequence analysis of the KIF17 tail domain revealed it contains a nuclear receptor box with a conserved LXXLL motif found in transcriptional co-activators. Expression of a 12 amino-acid peptide containing this motif was sufficient to inhibit ERR1 transcriptional activity and cell invasion, while deletion of this region from the KIF17 tail resulted in increased ERR1 activity. Together, these data suggest KIF17 modifies ERR1 function by two possible, non-exclusive mechanisms: (i) by regulating nuclear-cytoplasmic distribution or (ii) by competing with transcriptional co-activators for binding to ERR1. Thus targeting the ERR1-KIF17 interaction has potential as a novel strategy for treating breast cancer.

Additional Information

© 2017 Seneviratne et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Received: August 06, 2015; Accepted: May 12, 2017; Published: May 23, 2017. Author contributions: AMPBS designed and performed experiments and wrote the manuscript, ZT prepared reagents and performed experiments, FJ prepared reagents, initiated the yeast-2-hybrid screen and generated expression plasmids encoding yeast-2-hybrid positive clones, AH and PL performed the yeast-2-hybrid screen with JPB, WS produced genome-edited cell lines, GK conceived the project, designed experiments and wrote the manuscript. We thank Jean Marc Vanacker for providing the ERRE-Luc reporter construct and Vivek Mittal for providing MDA-MB-LM2 cells. We also thank Elisa Sanchez for assistance producing ERR3 plasmids. This work was supported by grants to GK from the Department of Defense Breast Cancer Research Program (BC095193, contract W81XWH-10-1-0095), the National Institutes of Health (NIGMS-R01GM087575) and the Irma T. Hirschl Trust. Work in the JPB lab was supported by La Ligue Contre le Cancer (Label Ligue), Canceropôle PACA and Institut Paoli-Calmettes. JPB is a scholar of Institut Universitaire de France.

Attached Files

Published - 18104-264202-4-PB.pdf

Files

18104-264202-4-PB.pdf
Files (5.9 MB)
Name Size Download all
md5:123040c41649fc60692a78a933a55173
5.9 MB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 25, 2023